Retrospective Study of Cisplatin/Carboplatin, 5-Fluorouracil Plus Cetuximab (EXTREME) for Advanced-stage Salivary Gland Cancer
| Autor: | TAKAFUMI NAKANO, RYUJI YASUMATSU, KAZUKI HASHIMOTO, RYOSUKE KUGA, TAKAHIRO HONGO, HIDETAKA YAMAMOTO, MIOKO MATSUO, TAKAHIRO WAKASAKI, RINA JIROMARU, TOMOMI MANAKO, SATOSHI TOH, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, YUICHIRO KURATOMI, HIDEOKI URYU, TORAHIKO NAKASHIMA, AKIHIRO TAMAE, RISA TANAKA, MASAHIKO TAURA, TORANOSHIN TAKEUCHI, TAKAMASA YOSHIDA, TAKASHI NAKAGAWA |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | In Vivo |
| ISSN: | 1791-7549 0258-851X |
| Popis: | Background/Aim: Surgery remains the standard treatment for salivary gland carcinoma (SGC). Our study investigated the association between epidermal growth factor receptor (EGFR) status in recurrent/metastatic SGC and the effectiveness of treatment with cisplatin/carboplatin and 5-fluorouracil plus cetuximab (EXTREME). Patients and Methods: We retrospectively collected 19 SGCs from patients treated with the EXTREME regimen. After analyzing EGFR expression and gene copy number gain, we evaluated the correlation between EGFR status and clinicopathological factors and prognosis. Results: EGFR overexpression was detected in 77.8% cases, but not statistically associated with clinicopathological factors or prognosis. EGFR gene copy number gain was detected in 16.7% cases, and statistically positively correlated with lymph node metastasis (p=0.0291). The best overall response was partial response in two cases, stable disease in 15, and progressive disease in one case. The EXTREME regimen was discontinued in all cases. Conclusion: Our results suggest that SGCs are positive for EGFR protein expression but the response rate to the EXTREME regimen was unremarkable. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|